A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)

NCT01991678 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment

Interventions

DRUG: 145 mg/m2 NKTR 102
DRUG: 120 mg/m2 NKTR 102
DRUG: 50 mg/m2 NKTR 102

Sponsor

Nektar Therapeutics